Sunday, June 14, 2015 6:23:10 PM
However, failure to promptly address the issues raised in the Warning Letter to the FDA’s satisfaction or to comply with U.S. medical device regulatory requirements in general could result in regulatory action being initiated by the FDA. These actions could include, among other things, delays in approval of any FDA applications, product seizures, injunctions and civil monetary penalties. Any such actions could disrupt our ongoing business and operations and potentially have a material adverse impact on our financial condition and operating results.
Everything I say and write is my opinion and my opinion only. Do your own due diligence when investing
Recent NEPH News
- Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 09:15:00 PM
- Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 02/29/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:17:43 PM
- Nephros Announces Results for Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/08/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:05:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:30:14 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:29:28 PM
- Nephros Hires Judy Krandel as Chief Financial Officer • GlobeNewswire Inc. • 11/01/2023 11:30:00 AM
- Nephros Schedules Third Quarter 2023 Financial Results Conference Call • GlobeNewswire Inc. • 10/25/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 08:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:15:27 PM
- Nephros Announces Results for Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/09/2023 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:00:51 PM
- Nephros Schedules Second Quarter 2023 Financial Results Conference Call • GlobeNewswire Inc. • 07/26/2023 11:30:00 AM
- Nephros Announces Results for Quarter Ended March 31, 2023 • GlobeNewswire Inc. • 05/10/2023 08:15:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM